| pubmed-article:54739 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:54739 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:54739 | lifeskim:mentions | umls-concept:C0439849 | lld:lifeskim |
| pubmed-article:54739 | lifeskim:mentions | umls-concept:C0014442 | lld:lifeskim |
| pubmed-article:54739 | lifeskim:mentions | umls-concept:C0004561 | lld:lifeskim |
| pubmed-article:54739 | lifeskim:mentions | umls-concept:C0039194 | lld:lifeskim |
| pubmed-article:54739 | lifeskim:mentions | umls-concept:C0011570 | lld:lifeskim |
| pubmed-article:54739 | lifeskim:mentions | umls-concept:C0280224 | lld:lifeskim |
| pubmed-article:54739 | lifeskim:mentions | umls-concept:C1533691 | lld:lifeskim |
| pubmed-article:54739 | pubmed:issue | 7955 | lld:pubmed |
| pubmed-article:54739 | pubmed:dateCreated | 1976-4-2 | lld:pubmed |
| pubmed-article:54739 | pubmed:abstractText | B and T lymphocytes have been measured in 100 women--71 patients with breast cancer and 29 controls--using sheep-erythrocyte rosetting techniques. Compared with controls (healthy women or patients with benign breast disease), there is a highly significant depression of T-cell percentage in all stages of breast cancer except locally advanced (stage 3) disease. These stage-3 cases seem to constitute a biologically distinct group. T-cell percentages in early (stage 1) patients overlap with those seen in stages 3 and 4, raising the possibility that there are in stage 1 two subpopulations of T-cell values that are associated with differences in subsequent tumour progression. B-lymphocyte levels are similar in all groups. Low T-cell levels return to normal after incubation with papain in virto but fall again after resuspending the treated lymphocytes in autologous (cancer) serum. The results suggest that T-cell depression is due to a masking factor on the surface of some T lymphocytes which is also present in the serum of cancer patients, and removable by enzyme digestion. | lld:pubmed |
| pubmed-article:54739 | pubmed:language | eng | lld:pubmed |
| pubmed-article:54739 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:54739 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:54739 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:54739 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:54739 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:54739 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:54739 | pubmed:issn | 0140-6736 | lld:pubmed |
| pubmed-article:54739 | pubmed:author | pubmed-author:RobertsG PGP | lld:pubmed |
| pubmed-article:54739 | pubmed:author | pubmed-author:HughesL ELE | lld:pubmed |
| pubmed-article:54739 | pubmed:author | pubmed-author:TeasdaleCC | lld:pubmed |
| pubmed-article:54739 | pubmed:author | pubmed-author:WhiteheadR... | lld:pubmed |
| pubmed-article:54739 | pubmed:author | pubmed-author:ThatcherJJ | lld:pubmed |
| pubmed-article:54739 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:54739 | pubmed:day | 14 | lld:pubmed |
| pubmed-article:54739 | pubmed:volume | 1 | lld:pubmed |
| pubmed-article:54739 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:54739 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:54739 | pubmed:pagination | 330-3 | lld:pubmed |
| pubmed-article:54739 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:54739 | pubmed:meshHeading | pubmed-meshheading:54739-Hu... | lld:pubmed |
| pubmed-article:54739 | pubmed:meshHeading | pubmed-meshheading:54739-Br... | lld:pubmed |
| pubmed-article:54739 | pubmed:meshHeading | pubmed-meshheading:54739-Pa... | lld:pubmed |
| pubmed-article:54739 | pubmed:meshHeading | pubmed-meshheading:54739-Ag... | lld:pubmed |
| pubmed-article:54739 | pubmed:meshHeading | pubmed-meshheading:54739-Im... | lld:pubmed |
| pubmed-article:54739 | pubmed:meshHeading | pubmed-meshheading:54739-Fe... | lld:pubmed |
| pubmed-article:54739 | pubmed:meshHeading | pubmed-meshheading:54739-Ad... | lld:pubmed |
| pubmed-article:54739 | pubmed:meshHeading | pubmed-meshheading:54739-Le... | lld:pubmed |
| pubmed-article:54739 | pubmed:meshHeading | pubmed-meshheading:54739-Mi... | lld:pubmed |
| pubmed-article:54739 | pubmed:meshHeading | pubmed-meshheading:54739-Cu... | lld:pubmed |
| pubmed-article:54739 | pubmed:meshHeading | pubmed-meshheading:54739-Ly... | lld:pubmed |
| pubmed-article:54739 | pubmed:meshHeading | pubmed-meshheading:54739-T-... | lld:pubmed |
| pubmed-article:54739 | pubmed:meshHeading | pubmed-meshheading:54739-Im... | lld:pubmed |
| pubmed-article:54739 | pubmed:meshHeading | pubmed-meshheading:54739-B-... | lld:pubmed |
| pubmed-article:54739 | pubmed:year | 1976 | lld:pubmed |
| pubmed-article:54739 | pubmed:articleTitle | T and B lymphocytes in breast cancer stage relationship and abrogation of T-lymphocyte depression by enzyme treatment in vitro. | lld:pubmed |
| pubmed-article:54739 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:54739 | pubmed:publicationType | In Vitro | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:54739 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:54739 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:54739 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:54739 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:54739 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:54739 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:54739 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:54739 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:54739 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:54739 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:54739 | lld:pubmed |
